These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
446 related articles for article (PubMed ID: 37028555)
1. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study. Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y Transplant Cell Ther; 2023 Jul; 29(7):456.e1-456.e11. PubMed ID: 37028555 [TBL] [Abstract][Full Text] [Related]
2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Zheng WS; Hu YL; Guan LX; Peng B; Wang SY Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943 [TBL] [Abstract][Full Text] [Related]
3. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627 [TBL] [Abstract][Full Text] [Related]
4. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study. Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P; Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473 [TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia. Al Hamed R; Labopin M; Daguindau E; Niittyvuopio R; Huynh A; Socié G; Srour M; Henri Bourhis J; Kröger N; Tholouli E; Choi G; Poiré X; Martin H; Rubio MT; Jindra P; Blaise D; Beelen D; Labussière-Wallet H; Nagler A; Bazarbachi A; Mohty M Cancer Med; 2022 Feb; 11(4):1068-1080. PubMed ID: 35048553 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Oran B; Cortes J; Beitinjaneh A; Chen HC; de Lima M; Patel K; Ravandi F; Wang X; Brandt M; Andersson BS; Ciurea S; Santos FP; de Padua Silva L; Shpall EJ; Champlin RE; Kantarjian H; Borthakur G Biol Blood Marrow Transplant; 2016 Jul; 22(7):1218-1226. PubMed ID: 27058617 [TBL] [Abstract][Full Text] [Related]
8. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758 [TBL] [Abstract][Full Text] [Related]
9. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760 [TBL] [Abstract][Full Text] [Related]
10. Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation. Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Kumar R; Minden MD; Chang H Biol Blood Marrow Transplant; 2020 Nov; 26(11):1995-2000. PubMed ID: 32712325 [TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Schmid C; Labopin M; Socié G; Daguindau E; Volin L; Huynh A; Bourhis JH; Milpied N; Cornelissen J; Chevallier P; Maertens J; Jindra P; Blaise D; Lenhoff S; Ifrah N; Baron F; Ciceri F; Gorin C; Savani B; Giebel S; Polge E; Esteve J; Nagler A; Mohty M; Blood; 2015 Oct; 126(17):2062-9. PubMed ID: 26351297 [TBL] [Abstract][Full Text] [Related]
12. Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Shouval R; Labopin M; Bomze D; Baerlocher GM; Capria S; Blaise D; Hänel M; Forcade E; Huynh A; Saccardi R; Milone G; Zuckerman T; Reményi P; Versluis J; Esteve J; Gorin NC; Mohty M; Nagler A Bone Marrow Transplant; 2020 Dec; 55(12):2244-2253. PubMed ID: 32388535 [TBL] [Abstract][Full Text] [Related]
13. The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation. Tang F; Zhao X; Ruan G; Jiang Q; Jiang H; Xu L; Wang Y; Zhang X; Liu K; Huang X Hematol Oncol; 2023 Oct; 41(4):733-742. PubMed ID: 37272204 [TBL] [Abstract][Full Text] [Related]
14. Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML. Wan L; Ding S; Xu M; Lv K; Du Y; Wu D; Xu M; Liu Y Int J Hematol; 2022 Nov; 116(5):731-743. PubMed ID: 35857193 [TBL] [Abstract][Full Text] [Related]
15. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation. Tang S; Shen H; Mao X; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X Int J Hematol; 2017 Oct; 106(4):552-561. PubMed ID: 28616699 [TBL] [Abstract][Full Text] [Related]
16. Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party. Bazarbachi A; Labopin M; Gedde-Dahl T; Remenyi P; Forcade E; Kröger N; Socié G; Craddock C; Bourhis JH; Versluis J; Yakoub-Agha I; Salmenniemi U; El-Cheikh J; Bug G; Esteve J; Nagler A; Ciceri F; Mohty M Clin Cancer Res; 2023 Nov; 29(21):4441-4448. PubMed ID: 37603683 [TBL] [Abstract][Full Text] [Related]
17. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation. Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446 [TBL] [Abstract][Full Text] [Related]
18. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546 [TBL] [Abstract][Full Text] [Related]
19. [Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation]. Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Pei RZ; Tang XW Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):552-557. PubMed ID: 30122013 [No Abstract] [Full Text] [Related]
20. [Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation]. Yang Z; Tian H; Xu Y; Qiu H; Chen S; Sun A; Wu D Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):94-8. PubMed ID: 24767158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]